Clinical Implications of Urinary C-Peptide Creatinine Ratio in Patients with Different Types of Diabetes

Table 3

The characters of the two patients who had a and without insulin or secretagogue treatment.

	Patient 1	Patent 2
Sex	Male	Female
Diagnosis age (yrs)	29	60
Age (yrs)	29	73
Diabetes duration (yrs)	0.6	13
BMI (kg/m^2)	21.9	19.5
SBP (mmHg)	96	135
DBP (mmHg)	60	70
WL (cm)	68	78
TG (mmol/L)	2.93	0.61
TC (mmol/L)	6.4	5.69
HDL-c (mmol/L)	1.10	1.92
LDL-c (mmol/L)	3.90	2.73
UA (μmol/L)	292	194
FBG (mmol/L)	9.4	5.13
FCP (nmol/L)	0.60	0.3
PCP (nmol/L)	0.71	1.77
FINS (μU/ml)	2.72	31.18
PINS (μU/ml)	5.92	8.20
UCPCR (nmol/mmol)	0.11	0.11
A1C (%)	13.5	6.6
Complications
DN (%)	—	—
DR (%)	—	—
DPN (%)	+	—
Treatment (%)
	Metformin 500 mg t.i.d.	Metformin 250 mg t.i.d.
	Acarbose tablet 50 mg t.i.d.	Acarbose tablet 50 mg t.i.d.

Data is median (interquartile range), unless otherwise stated. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; WL: waistline; TG: triglyceride; TC: total cholesterol; HDL-c: high-density lipoprotein-cholesterol; LDL-c: low-density lipoprotein-cholesterol; UA: uric acid; FBG: fasting blood glucose; FCP: fasting C-peptide; PCP: postprandial C-peptide; A1C: HbA1c; DN: diabetic nephropathy; DR: diabetic retinopathy; DPN: diabetic peripheral neuropath; OHA: oral hypoglycemic agent. Statistical significance.